Roche's tiragolumab flops in another Phase III lung cancer trial

By Yahoo! Finance   |   1 year ago
Roche's tiragolumab flops in another Phase III lung cancer trial

Roche's immune checkpoint inhibitor tiragolumab, in combination with Tecentriq, failed to meet the primary endpoint of overall survival in the Phase III SKYSCRAPER-01 trial for lung cancer.

Read More

Did you find this insightful?